{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:09:49Z","timestamp":1774638589606,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Labelled Comp Radiopharmac"],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:p>Gonadotropin\u2010releasing hormone (GnRH) receptor antagonists are an important class of compounds designed to block the pituitary gland from synthesizing follicle\u2010stimulating hormone and luteinizing hormone for the treatment of sex hormone dependent disorders. Elagolix (ABT\u2010620) is currently approved for the treatment of pain associated with endometriosis and as a combination with estradiol and norethindrone acetate is approved for management of heavy menstrual bleeding due to uterine fibroids. In order to support the development of elagolix, we prepared [<jats:sup>3<\/jats:sup>H]elagolix for preclinical metabolism studies and [<jats:sup>14<\/jats:sup>C]elagolix for environmental risk assessment studies.<\/jats:p>","DOI":"10.1002\/jlcr.3908","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T21:28:33Z","timestamp":1614979713000},"page":"254-261","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synthesis of [H\u20103]\u2010 and [C\u201014]\u2010labeled elagolix"],"prefix":"10.1002","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-093X","authenticated-orcid":false,"given":"Eric D.","family":"Soli","sequence":"first","affiliation":[{"name":"Department of Process Chemistry, Radiochemistry AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce W.","family":"Surber","sequence":"additional","affiliation":[{"name":"Department of Process Chemistry, Radiochemistry AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee D.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Process Chemistry, Radiochemistry AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"AbbVie Inc.Orilissa\u2122 (elagolix) [United States package insert]. North Chicago IL.2018.https:\/\/www.rxabbvie.com\/pdf\/orilissa_pi.pdf"},{"key":"e_1_2_7_3_1","unstructured":"AbbVie Inc.ORIAHNN\u2122 (elagolix estradiol and norethindrone acetate capsules; elagolix capsules) [United States package insert]. North Chicago IL;2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213388s000lbl.pdf"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)47959-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-011-1309-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00833-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3845"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00840-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00400"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743447"},{"key":"e_1_2_7_11_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).Environmental assessment: Questions and answers regarding drugs with estrogenic androgenic or thyroid activity. March2016 CMChttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/environmental-assessment-questions\u2010and\u2010answers\u2010regarding\u2010drugs\u2010estrogenic\u2010androgenic\u2010or\u2010thyroid"},{"issue":"23","key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/jm8006454","article-title":"Discovery of sodium R\u2010(+)\u20104\u2010{2\u2010[5\u2010(2\u2010fluoro\u20103\u2010methoxyphenyl)\u20103\u2010(2\u2010fluoro\u20106\u2010[trifluoromethyl]benzyl)\u20104\u2010methyl\u20102,6\u2010dioxo\u20103,6\u2010dihydro\u20102H\u2010pyrimidin\u20101\u2010yl]\u20101\u2010phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin\u2010releasing hormone receptor","volume":"51","author":"Chen C","year":"2008","journal-title":"J Med Chem"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01660a038"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol900131q"},{"key":"e_1_2_7_15_1","unstructured":"SchreinerE FelzmannW NerdingerS MartinN.Preparation of acid addition salt of elagolix and related compounds. EP3572406 2019."},{"key":"e_1_2_7_16_1","unstructured":"ChauhanN HoR KrugerA et al.Elagolix sodium compositions and processes. US20200024239 2020."},{"key":"e_1_2_7_17_1","unstructured":"GallagherDJ TreiberLR HughesRM et al.Processes for the preparation of uracil derivatives. US8765948 2014."},{"key":"e_1_2_7_18_1","unstructured":"WangP LiP GuX et al.Processes for the preparation of elagolix. WO2019112968 2019."}],"container-title":["Journal of Labelled Compounds and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jlcr.3908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jlcr.3908","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jlcr.3908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T17:49:00Z","timestamp":1760636940000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jlcr.3908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,15]]}},"alternative-id":["10.1002\/jlcr.3908"],"URL":"https:\/\/doi.org\/10.1002\/jlcr.3908","archive":["Portico"],"relation":{},"ISSN":["0362-4803","1099-1344"],"issn-type":[{"value":"0362-4803","type":"print"},{"value":"1099-1344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"2020-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}